EARS - Auris Medical Holding AG

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5538
-0.0112 (-1.98%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close0.5650
Open0.5610
Bid0.5650 x 2000
Ask0.5700 x 900
Day's Range0.5500 - 0.5900
52 Week Range0.2300 - 6.6000
Volume1,469,762
Avg. Volume7,483,468
Market Cap17.998M
Beta (3Y Monthly)-3.13
PE Ratio (TTM)N/A
EPS (TTM)-1.3270
Earnings DateNov 8, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • ACCESSWIRE3 days ago

    New Healthcare Trends Pushing Stocks Higher On Thursday

    CORAL GABLES, FL / ACCESSWIRE / December 6, 2018 / Analyst firms like Global Market Insights are expecting a lot as far as the future of healthcare is concerned. The firm reports that the healthcare industry ...

  • GlobeNewswire3 days ago

    Auris Medical Announces Acquisition of Orphan Drug Designation and Secures Rights to In-License Additional Patents Related to Betahistine

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced a strategic expansion for its intranasal betahistine development program. In two related transactions, the Company has acquired an Orphan Drug Designation for betahistine in the treatment of obesity associated with Prader-Willi syndrome (PWS) and signed a binding letter of intent to in-license exclusive rights to two US Patents relating to the use of betahistine for the treatment of depression and attention-deficit / hyperactivity disorder (ADHD), respectively.

  • ACCESSWIRE13 days ago

    Biotech and Cannabis Stocks to Watch

    With Thanksgiving behind us here's a few biotech/ healthcare companies that might be worth looking at before after your meal HENDERSON, NV / ACCESSWIRE / November 26, 2018 / Today we are highlighting: ...

  • GlobeNewswire16 days ago

    Detailed Research: Economic Perspectives on Wingstop, Marlin Business Services, Aware, Zynerba Pharmaceuticals, Auris Medical Holding AG, and Gulf Island Fabrication — What Drives Growth in Today's Competitive Landscape

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • ACCESSWIRE18 days ago

    Today's Research Reports on Trending Tickers: Auris Medical and Bioblast Pharma

    NEW YORK, NY / ACCESSWIRE / November 21, 2018 / It was a day of gains for biotech stocks Auris Medical Holding and Bioblast Pharma after the companies announced positive developments. Bioblast announced it has executed a definitive agreement to acquire Enlivex Therapeutics while Auris Medical announced the results of a Pre-IND meeting with the FDA. Auris Medical Holding AG shares were up nearly 36% on Tuesday on roughly 13.7 million shares traded.

  • GlobeNewswire19 days ago

    Auris Medical Announces Results of Pre-IND Meeting With FDA For AM-201 Program in Olanzapine-Induced Weight Gain

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced the results of its pre-Investigational New Drug (pre-IND) meeting with the United States Food & Drug Administration (FDA), where the FDA addressed the Company's questions and provided guidance on its AM-201 program with intranasal betahistine for the prevention of olanzapine-induced weight gain. In its written response, the FDA supported the planned conduct of a multiple dose Phase 1 trial with AM-201 administered to healthy subjects in combination with olanzapine to evaluate the pharmacokinetics, pharmacodynamics, and safety, and to establish proof-of-concept.

  • Associated Press24 days ago

    Auris: 3Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 14 cents. The company's shares closed at 63 cents. A year ago, they were trading at $7.39. _____ This story was generated ...

  • GlobeNewswire24 days ago

    Auris Medical Reports Third Quarter 2018 Financial Results and Provides Business Update

    Positive outcomes from second Phase 1 trial with intranasal betahistine Further evidence for betahistine's preventive effects in antipsychotic-induced weight gain.

  • GlobeNewswirelast month

    Auris Medical to Report Third Quarter 2018 Financial Results and Provide Business Update on Thursday, November 15, 2018

    Zug, Switzerland, November 08, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.

  • ACCESSWIRElast month

    Today's Research Reports on Trending Tickers: Loxo Oncology and Auris Medical Holding

    NEW YORK, NY / ACCESSWIRE / November 2, 2018 / U.S. markets rallied on Thursday, with the S&P 500 Index logging its first 3-day win streak in six weeks, as trade concerns between the U.S. and China continued ...

  • GlobeNewswirelast month

    Edison issues initiation on Auris Medical Holding (EARS)

    LONDON, Nov. 01, 2018 -- Auris Medical (EARS) is a clinical-stage biopharmaceutical company developing pharmacotherapies for neurologic disorders of the inner ear. The.

  • GlobeNewswire2 months ago

    Auris Medical Announces Positive Results From Second Phase 1 Clinical Trial With Intranasal Betahistine

    Auris Medical Holding AG (EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in neurotology and mental health supportive care, today announced positive results from the second Phase 1 trial evaluating intranasal betahistine in healthy volunteers. The study results demonstrated superior bioavailability over a range of four intranasal betahistine doses compared to oral betahistine, with plasma exposure being 6 to 29 times higher (p-value between 0.056 and p

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Agile Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 16, 2018 / Biotech stocks Auris Medical Holding and Agile Therapeutics were both seeing big gains on Monday. Traders are waiting for an update from Auris Medical on Wednesday while Agile recently concluded its formal dispute resolution with the FDA over the complete response letter issued for the new drug application of Twirla. Auris Medical Holding AG shares were skyrocketing on Monday with gains of 40.82% and an additional 23.19% in after-hours trading.

  • Why Auris Medical Stock Is Soaring Today
    InvestorPlace2 months ago

    Why Auris Medical Stock Is Soaring Today

    Auris Medical stock (NASDAQ:EARS) went gangbusters to kick off the week even though the company did not have any announcements or news surrounding it on Monday.

  • GlobeNewswire2 months ago

    Auris Medical to provide update on intranasal betahistine program on Wednesday, October 17, 2018

    Zug, Switzerland, October 12, 2018 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical.

  • ACCESSWIRE2 months ago

    Auris Medical Shares Gain on Initiated Coverage, Analysts Review and Target

    NEW YORK, NY / ACCESSWIRE / October 9, 2018 / Traders News Source, a leading independent equity research, and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Auris Medical Holding and Menlo Therapeutics

    NEW YORK, NY / ACCESSWIRE / October 9, 2018 / No news from Auris Medical Holding yet shares were skyrocketing on Monday. The company has been on a rocket since announcing in late August feedback from a ...

  • Associated Press4 months ago

    Auris: 2Q Earnings Snapshot

    On a per-share basis, the Zug, Switzerland-based company said it had a loss of 51 cents. The company's shares closed at 28 cents. A year ago, they were trading at $7.70. _____ This story was generated ...

  • ACCESSWIRE5 months ago

    Complimentary Technical Snapshots on OHR Pharma and Three More Biotech Stocks

    LONDON, UK / ACCESSWIRE / July 13, 2018 / If you want a free Stock Review on OHRP sign up now at www.wallstequities.com/registration. For today, WallStEquities.com observes Auris Medical Holding AG (EARS), NewLink Genetics Corp. (NLNK), OHR Pharmaceutical Inc. (OHRP), and Omeros Corp. (OMER). The industry includes the manufacturing and marketing of drugs as a result of direct research and development.

  • ACCESSWIRE6 months ago

    Free Technical Reports on Arrowhead Pharma and Three Additional Biotech Equities

    On Tuesday, June 12, 2018, the NASDAQ Composite and the S&P 500 edged 0.57% and 0.17% higher, respectively at the closing bell, while the Dow Jones Industrial Average stayed bearish, finishing marginally lower by 0.01%. Taking into consideration yesterday's market sentiment, WallStEquities.com assessed the following Biotechnology equities this morning: Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR), Atara Biotherapeutics Inc. (NASDAQ: ATRA), Athersys Inc. (NASDAQ: ATHX), and Auris Medical Holding AG (NASDAQ: EARS).